A Pfizer drug that failed to thrive as a treatment for HIV may now present a great hope for a deadly consequence of the bone marrow transplants used to treat blood cancers such as leukemia, myeloma, and lymphoma, according to a small study of 38 patients published this evening in the New England Journal of Medicine.
